Moexipril
Clinical data | |
---|---|
Trade names | Univasc |
AHFS/Drugs.com | Monograph |
MedlinePlus | a695018 |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Hepatic (active metabolite, moexiprilat) | |
Elimination half-life | 1 hour; 2-9 hours (active metabolite) |
Excretion | 50% (faeces), 13% (urine) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H34N2O7 |
Molar mass | 498.576 g·mol−1 |
(what is this?) (verify) |
Moexipril was an
It works by inhibiting the conversion of
It was patented in 1980 and approved for medical use in 1995.[4] Moexipril is available from Schwarz Pharma under the trade name Univasc.[3][5]
Side effects
Moexipril is generally well tolerated in elderly patients with hypertension.[6] Hypotension, dizziness, increased cough, diarrhea, flu syndrome, fatigue, and flushing have been found to affect less than 6% of patients who were prescribed moexipril.[3][6]
Mechanism of action
As an ACE inhibitor, moexipril causes a decrease in ACE. This blocks the conversion of angiotensin I to angiotensin II. Blockage of angiotensin II limits hypertension within the vasculature. Additionally, moexipril has been found to possess cardioprotective properties. Rats given moexipril one week prior to induction of
Pharmacology
Moexipril is available as a
Moexipril is highly
It has additional PDE4-inhibiting effects.[16]
Synthesis
The synthesis of the all-important dipeptide-like side chain involves alkylation of the tert-butyl ester of L-alanine (2) with ethyl 2-bromo-4-phenylbutanoate (1); the presominane of the desired isomer is attributable to asymmetric induction from the adjacent chiral center. Reaction of the product with hydrogen chloride then cleaves the tert-butyl group to give the half acid (3).[19] Coupling of that acid to the secondary amine on tetrahydroisoquinoline (4) gives the corresponding amine. The tert-butyl ester in this product is again cleaved with hydrogen chloride to afford moexipril (5).
References
- ISBN 978-1-4027-1740-6. Retrieved 2009-10-09.
- ^ .
- ^ a b c Rodgers K, Vinson MC, Davis MW (1996). Breakthroughs: New drug approvals of 1995 -- part 1 (Report). Vol. 140. Advanstar Communications, Inc. p. 84.
- ISBN 9783527607495.
- ISBN 978-0-7817-2845-4. Retrieved 2009-10-09.
- ^ PMID 8583466.
- PMID 8837552.
- ^ PMID 9488609.
- ^ PMID 7545893.
- PMID 1735595.
- S2CID 27296727.
- S2CID 24853463.
- PMID 17266629.
- PMID 17583172.
- ^ PMID 11837383.
- PMID 23473803.
- Warner-Lambert).
- PMID 3020249.
- .